Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Novartis Gains Phase II COPD Agent In Deal Worth Up To $375 Mil.

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Novartis will assume Phase III testing of anti-muscarinic from U.K. companies Vectura and Arakis. AD 237 will be evaluated in head-to-head comparison against Pfizer/Boehringer Ingelheim's Spiriva; companies believe AD 237 has a better safety profile than tiotropium.

You may also be interested in...



Vectura, Unilever Establish Specialty Pharmaceutical Company

PharmaKodex will apply novel oral and dermal delivery mechanisms to existing therapies.

Oncology Pilot To Highlight Disagreements Between US FDA And Sponsor For Advisory Committees

'Point/Counterpoint' program grew out of Assessment Aid initiative in the Oncology Center of Excellence and will be unveiled at an upcoming ODAC meeting.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS061982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By